[{"id":"e5e2b950-7554-4958-b2db-713f66c51761","acronym":"","url":"https://clinicaltrials.gov/study/NCT03280030","created_at":"2021-01-18T16:11:51.281Z","updated_at":"2025-02-25T15:42:59.213Z","phase":"Phase 2","brief_title":"A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML","source_id_and_acronym":"NCT03280030","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 04/06/2018","start_date":" 04/06/2018","primary_txt":" Primary completion: 11/14/2022","primary_completion_date":" 11/14/2022","study_txt":" Completion: 11/14/2022","study_completion_date":" 11/14/2022","last_update_posted":"2025-02-11"},{"id":"84edb0cb-23b4-41c9-a4af-3815707a7019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958719","created_at":"2025-02-26T07:45:46.896Z","updated_at":"2025-02-26T07:45:46.896Z","phase":"Phase 2","brief_title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","source_id_and_acronym":"NCT05958719","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" IFNG • IL6 • TNFA • IL10 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2024-12-30"},{"id":"5c7bafb8-a49c-4d34-97a5-3ed538c792ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05832320","created_at":"2023-04-27T14:04:55.563Z","updated_at":"2024-07-02T16:35:04.431Z","phase":"","brief_title":"Optimum Induction Therapy of Low-risk APL","source_id_and_acronym":"NCT05832320","lead_sponsor":"Peking University People's Hospital","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-10"},{"id":"737bf8ac-224d-4890-9289-ef1407053b41","acronym":"VITAL","url":"https://clinicaltrials.gov/study/NCT02658487","created_at":"2021-01-18T12:56:58.878Z","updated_at":"2024-07-02T16:35:06.085Z","phase":"Phase 2","brief_title":"Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia","source_id_and_acronym":"NCT02658487 - VITAL","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" SRC","pipe":"","alterations":" ","tags":["SRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-03"},{"id":"f217b7d9-3e47-4a87-b909-a8c4c9782009","acronym":"DaunoDouble","url":"https://clinicaltrials.gov/study/NCT02140242","created_at":"2021-07-17T10:53:01.305Z","updated_at":"2024-07-02T16:35:36.908Z","phase":"Phase 3","brief_title":"Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML","source_id_and_acronym":"NCT02140242 - DaunoDouble","lead_sponsor":"Technische Universität Dresden","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 721","initiation":"Initiation: 04/16/2014","start_date":" 04/16/2014","primary_txt":" Primary completion: 04/25/2022","primary_completion_date":" 04/25/2022","study_txt":" Completion: 04/25/2022","study_completion_date":" 04/25/2022","last_update_posted":"2023-09-15"},{"id":"344dd84f-cbb2-4195-9057-7e6bb67aba39","acronym":"","url":"https://clinicaltrials.gov/study/NCT01238211","created_at":"2021-01-18T04:59:02.957Z","updated_at":"2024-07-02T16:35:54.402Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01238211","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 12/14/2010","start_date":" 12/14/2010","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 03/15/2021","study_completion_date":" 03/15/2021","last_update_posted":"2023-03-01"},{"id":"7f0b2055-2792-4c2b-a9ad-9dc67fd8b63b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02914977","created_at":"2021-01-18T14:18:37.925Z","updated_at":"2024-07-02T16:36:18.463Z","phase":"Phase 1","brief_title":"Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia","source_id_and_acronym":"NCT02914977","lead_sponsor":"Tara Lin","biomarkers":" CTNNB1","pipe":"","alterations":" ","tags":["CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 04/03/2019","primary_completion_date":" 04/03/2019","study_txt":" Completion: 07/15/2021","study_completion_date":" 07/15/2021","last_update_posted":"2022-01-14"},{"id":"cd2a2120-8206-4bc7-97e5-99651be9b52b","acronym":"Ara-C","url":"https://clinicaltrials.gov/study/NCT01191541","created_at":"2021-02-21T23:52:19.111Z","updated_at":"2024-07-02T16:36:26.660Z","phase":"Phase 4","brief_title":"Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)","source_id_and_acronym":"NCT01191541 - Ara-C","lead_sponsor":"Xiaofan Zhu","biomarkers":" RARA","pipe":"","alterations":" ","tags":["RARA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2021-08-10"},{"id":"58ca73ff-c84e-4c36-8b48-77303f0651d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01627041","created_at":"2021-01-18T06:59:10.297Z","updated_at":"2024-07-02T16:36:28.861Z","phase":"Phase 2","brief_title":"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01627041","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RARA • CBFB","pipe":"","alterations":" ","tags":["RARA • CBFB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • decitabine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 09/16/2011","start_date":" 09/16/2011","primary_txt":" Primary completion: 02/11/2016","primary_completion_date":" 02/11/2016","study_txt":"","study_completion_date":"","last_update_posted":"2021-06-21"},{"id":"5d967763-a9a0-47a7-8409-811f7afd860a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01041703","created_at":"2021-01-18T04:05:21.012Z","updated_at":"2024-07-02T16:37:15.691Z","phase":"Phase 3","brief_title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01041703","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • decitabine • daunorubicin • clofarabine"],"overall_status":"Recruiting","enrollment":" Enrollment 747","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-08"},{"id":"75427955-b93e-415c-9f67-79663c7d466d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00408603","created_at":"2021-01-18T01:25:56.750Z","updated_at":"2024-07-02T16:37:19.503Z","phase":"Phase 2","brief_title":"Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer","source_id_and_acronym":"NCT00408603","lead_sponsor":"Sunesis Pharmaceuticals","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Qinprezo (vosaroxin)"],"overall_status":"Completed","enrollment":" Enrollment 183","initiation":"Initiation: 12/20/2006","start_date":" 12/20/2006","primary_txt":" Primary completion: 06/09/2010","primary_completion_date":" 06/09/2010","study_txt":" Completion: 06/09/2010","study_completion_date":" 06/09/2010","last_update_posted":"2017-07-27"}]